Cagrilintide

  • Advanced Fermentation Platforms
  • Professional CDMO Service
  • GMP-Compliant Pharmaceutical Purity
Inquiry Now
Premium API

Cagrilintide API

Cagrilintide is a novel pharmacological drug that targets metabolic disorders, particularly obesity and type 2 diabetes. Its design refines the natural peptide hormone amylin, modifying the structure to overcome inherent limitations, such as instability and a short plasma half-life. This innovative molecule represents a significant advancement in the development of drugs for weight management and metabolic control. The research and development of cagrilintide production are based on decades of preclinical structure-activity relationship studies and clinical pharmacokinetic evaluations.

Cagrilintide
Premium API

Cagrilintide

  • Peptide Name: Cagrilintide
  • CAS Number: 1415456-99-3
  • Formula: C194H312N45O59S2
  • Molecular Weight: 4409g/mol
  • Sequence: KCNTA TCATQ RLAEF LRHSS NNFGP ILPPT NVGSN TP
  • Purity: 98%
  • Type: Drug Peptides, Synthetic peptide,
    Amylin and calcitonin receptor co-agonists
Premium API

Cagrilintide Description

Cagrilintide is a long-acting amylin analog, it can mimic the effect of natural hormone amylin, and regulate appetite and food intake. Cagrilitide normally acts on the postrema area in the brain, enhances satiety, reduce food consumption, and loss weight. It has potential in treatment of type 2 diabetes and obesity, usually in combination with semaglutide (like CargiSema). As native amylin is propensity to aggregation as amyloid fibrils, and has short half-life in clinical utility. Cargrilintide addresses these concern by structural modification like lipidation and backbones. These modifications enhance stability and prolong biological activity, enable sustained receptor activation with less dosing frequency. Therefore, cargrilintide has favorable pharmacokinetic properties with extended half-life, predictable absorption, significant reduction of amyloid fibrils. It is a crucial breakthrough in earlier amylin-based therapies.

Cagrilintide-2000

Clinical Application

Cargrilintide is a versatile agent in treatment of complex metabolic disorders. Its dual receptor activity not only imparts weight-loss but also improves glycemic contral. It has the favorable profile in application of obesity management and type 2 diabetes.

  • Obesity and overweight management: cagrilintide is aneffective agent for reducing body weight, it has potent action on satiety centers.
  • Type 2 diabetes: cagrilintide has the ability to improve glycemic control, it can reduce glycated hemoglobin (HbA1c) levels once administered either alone or in combination with other agents (semaglutide).
Clinical Application

Pharmacology Classification

Cagrilintide is classified as dual amylin and calcitonin receptor agonist(DACRA), its unique receptor has distinct position in metabolic therapeutics. It can activate both the amylin receptor and the calcitonin receptor.

This dual agonism distinguishes from the traditional amylin analogs or GLP-1 receptor agonists, as its multiple pathways to modulate energy balance and glucose metabolism. Therefore, cargrilintide belongs to the advanced therapeutic category at managing body-weight and glycemic control, its pharmacodynamic profile enhances the utility for treatment of obesity and type Ⅱ diabetes.

Pharmacology Classification
Premium API

Genetic Synthesis of Cagrilintide

Morebio has cutting-edge manufacturing facilities in an industrial scale, this increase our production capability significantly. Our maximum batch size of cagrilintide API can reach to 2.1 kg, and 200 kg in total per year. Even in pilot scale, we also have production capability of 30g. The purity of semaglutide API in Morebio can reach more than 98%, our advanced manufacturing technology controls the impurities less than 2%.

our Quality

Quality Insurance

  • Morebio has the stringent control standards in manufacturing process
  • Available in bulk quantities for global demands
  • Adheres to US FDA, EMA, GMP guidelines

Mechanism

  • Effective oral dosage forms to improve oral absorption rate.
  • Long-acting injections to prolong the action time of peptide drugs.
Quality Assurance
Cagrilintide Reference

Action Mode

Morebio has cutting-edge manufacturing facilities in an industrial scale, this increase our production capability significantly. Our maximum batch size of cagrilintide API can reach to 2.1 kg, and 200 kg in total per year. Even in pilot scale, we also have production capability of 30g. The purity of semaglutide API in Morebio can reach more than 98%, our advanced manufacturing technology controls the impurities less than 2%.

Amylin Receptor Activation

Indication

Cagrilintide mimics native amlyin, binds to amlyin receptor predominantly in the postrema area and regions of brain with appetite regulation. This binding enhance satiety signals, reduce food instant, and loss weight subsequently. In addition, this activation also improve postprandial glucose control by modulating glucagon release and slowing gastric emptying.

Calcitonin Receptor Activation

Action Mode

Although traditional calcitonin receptors are only associated with calcium homeostasis, cagrilintide activation of calcitonin receptor add another metabolic regulation. In this dual receptor agonism, calcitonin activation by cagrilintide results in the overall heightened metabolic response, enhanced weight loss.

Through these actions, cagirlintide interacts with both central and peripheral pathways. The central activation on the hypothalamus contributes to robust regulation of appetite and satiety, while peripheral effects on the gastrointestinal system lead to improved glycemic outcomes. Consequently, cargrilintide provides superior long-term efficacy in weight loss and glucose homeostasis, as observation in comparison with other agents. Its dual action solidifies the unique profile in metabolic drugs and forms the rationales within the amylin analog for its classification.